Tamene Sarah, Dalhoff Kim, Schwarz Peter, Backer Vibeke, Aanaes Kasper
Department of Otorhinolaryngology, Head & Neck Surgery and Audiology, Rigshospitalet and Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Department of Clinical Pharmacology, Bispebjerg and Frederiksberg University Hospital, Copenhagen, Denmark.
Eur Clin Respir J. 2023 Aug 4;10(1):2240511. doi: 10.1080/20018525.2023.2240511. eCollection 2023.
When first-line chronic rhinosinusitis (CRS) treatment fails, patients can either be treated with oral or injected systemic corticosteroids. Although the EPOS and international guidelines for CRS do not mention injected corticosteroids, it is commonly used by ear, nose, and throat specialists. While the risks of systemic corticosteroids, in general, are known, the pros and cons of injected and oral corticosteroids (OCS) in CRS treatment are unclear.
A systematic review of studies that report the effects and/or side effects of injected and oral corticosteroids in the treatment of CRS was made according to the PRISMA guidelines.
Altogether, 48 studies were included, only five studies reported on injected corticosteroids, and five attended with side effects. Three studies found beneficial effects of OCS perioperatively on sinus surgery, while four articles found no effect. Nineteen articles reported that OCS resulted in an improvement in symptoms. Two articles presented a longer-lasting effect of injected corticosteroids than OCS. Three studies reported adverse side effects of systemic corticosteroids, while two studies showed no adverse side effects. One study showed less adrenal suppression after injected corticosteroids compared to OCS. The evidence is not strong but shows a positive effect of systemic corticosteroids that lasts longer with injections.
Although systemic corticosteroids are widely used to treat CRS, there is a lack of studies comparing the OCS and injected corticosteroids. The evidence is sparse, however, injected steroids show longer effects with fewer side effects. An RCT study is needed to compare OCS and injected corticosteroids.
当一线慢性鼻-鼻窦炎(CRS)治疗失败时,患者可接受口服或注射用全身性糖皮质激素治疗。尽管欧洲鼻窦炎和鼻息肉诊疗指南(EPOS)及CRS国际指南未提及注射用糖皮质激素,但耳鼻喉科专家却普遍使用。虽然全身性糖皮质激素的风险总体上是已知的,但注射用和口服糖皮质激素(OCS)在CRS治疗中的利弊尚不清楚。
根据PRISMA指南,对报告注射用和口服糖皮质激素治疗CRS的效果和/或副作用的研究进行系统评价。
共纳入48项研究,仅有5项研究报告了注射用糖皮质激素,其中5项伴有副作用。3项研究发现围手术期OCS对鼻窦手术有有益效果,而4篇文章未发现效果。19篇文章报告OCS可改善症状。2篇文章指出注射用糖皮质激素的效果比OCS更持久。3项研究报告了全身性糖皮质激素的不良副作用,而2项研究未显示不良副作用。1项研究表明,与OCS相比,注射用糖皮质激素后的肾上腺抑制作用较小。证据虽不充分,但显示全身性糖皮质激素注射后效果更持久且有积极作用。
尽管全身性糖皮质激素被广泛用于治疗CRS,但缺乏比较OCS和注射用糖皮质激素的研究。证据不足,不过注射用类固醇显示出效果更持久且副作用更少。需要进行一项随机对照试验(RCT)研究来比较OCS和注射用糖皮质激素。